Skip to main content
SpringerLink
Log in

Peritoneal Mesothelioma

  • Chapter
Treatment of Peritoneal Surface Malignancies

Part of the book series: Updates in Surgery ((UPDATESSURG))

  • 916 Accesses

Abstract

Diffuse malignant peritoneal mesothelioma (DMPM) is an exceedingly uncommon tumor arising from mesothelial cells. Macroscopically, the disease is characterized by thousands of small tumor nodules that grow to form plaques, masses, or layers covering all peritoneal surfaces. DMPM has been considered a pathological entity without effective treatment options until the 1990s, when initial surgical experiences integrating cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) showed a significant impact on patient prognosis [1–3]. These encouraging results prompted clinical and basic science researchers to intensify their efforts in an attempt to identify new prognostic factors and therapeutic targets to optimize patient selection for treatment and therapeutic strategies. The translation of these advancements into clinical practice will be the challenge for the coming years [4, 5]. Treatment guidelines and investigational perspectives concerning DMPM were defined by the Consensus Conference, Milan (4–6 December 2006) [6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Feldman AL, Libutti SK, Pingpank JF et al (2003) Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21:4560–4567

    Article  CAS  PubMed  Google Scholar 

  2. Sugarbaker PH, Yan TD, Stuart OA, Yoo D (2006) Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 32:686–691

    Article  CAS  PubMed  Google Scholar 

  3. Deraco M, Nonaka D, Baratti D et al (2006) Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13:229–237

    Article  PubMed  Google Scholar 

  4. Deraco M, Baratti D, Zaffaroni N et al (2007) Advances in clinical research and management of diffuse peritoneal mesothelioma. Recent Results Cancer Res 169:137–155

    CAS  PubMed  Google Scholar 

  5. Zaffaroni N, Costa A, Pennati M et al (2007) Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol 29:453–466

    CAS  PubMed  Google Scholar 

  6. Deraco M, Bartlett D, Kusamura S, Baratti D (2008) Consensus statement on peritoneal mesothelioma. J Surg Oncol 98:268–272

    Article  PubMed  Google Scholar 

  7. European Network of Cancer Registries. Eurocim Version 4.0. European Incidence Database V2.3, CI5 Dictionary (2001). Lyon, France: IARC

    Google Scholar 

  8. Surveillance, Epidemiology, and End Results (SEER) Program. http://www.seer.cancer.gov

    Google Scholar 

  9. Boffetta P (2007) Epidemiology of peritoneal mesothelioma: a review. Annals of Oncology 18:985–990

    Article  CAS  PubMed  Google Scholar 

  10. Peto J, Decarli A, La Vecchia C et al (1999) The European mesothelioma epidemic. Br J Cancer 79:666–672

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Spirtas R, Heineman EF, Bernstein L et al (1994) Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 51:804–811

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Sugarbaker PH, Welch LS, Mohamed F, Glehen O (2003) A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 12:605–621

    Article  Google Scholar 

  13. Gazdar AF, Carbone M (2003) Molecular pathogenesis of mesotheliom and its relationship to Simian virus 40. Clin Lung Cancer 5:177–181

    Article  PubMed  Google Scholar 

  14. Roushdy-Hammady I, Siegel J, Emri S et al (2001) Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357:444–445

    Article  CAS  PubMed  Google Scholar 

  15. de Pangher V, Recchia L, Cafferata M et al (2010) Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 21:348–353

    Article  Google Scholar 

  16. Yan TD, Haveric N, Carmignani CP et al (2005) Abdominal Computed Tomography Scans in the Selection of Patients with Malignant Peritoneal Mesothelioma for Comprehensive Treatment with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy. Cancer 103:839–849

    Article  PubMed  Google Scholar 

  17. Husain AN, Colby T, Ordonez N et al (2013) Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 137:647–667

    Article  PubMed  Google Scholar 

  18. Weiss SW (1994) World health Organization International Histological Classification of Tumors: Histological typing of soft tissue tumors. Springer-Verlag, Berlin

    Book  Google Scholar 

  19. King J, Thatcher N, Pickering C, Hasleton P (2006) Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 49:561–568

    Article  CAS  PubMed  Google Scholar 

  20. Deraco M, Baratti D, Cabras AD et al (2010) Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol 2:76–84

    Article  PubMed Central  PubMed  Google Scholar 

  21. Yan TD, Deraco M, Elias D et al (2011) A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer 117:1856–63

    Article  Google Scholar 

  22. Robinson BWS, Creaney J, Lake R et al (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362:1612–6

    Article  CAS  PubMed  Google Scholar 

  23. Baratti D, Kusamura S, Martinetti A et al (2007) Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 14:500–508

    Article  PubMed  Google Scholar 

  24. Deraco M, Baratti D, Hutanu I et al (2013) The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 20:1093–1100

    Article  PubMed  Google Scholar 

  25. Berghmans T, Paesmans M, Lalami Y et al (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38:111–121

    Article  CAS  PubMed  Google Scholar 

  26. Jänne PA, Wozniak AJ, Belani CP et al (2005) Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 7:40–46

    Article  PubMed  Google Scholar 

  27. Carteni G, Manegold C, Martin Garcia G et al (2009) Malignant peritoneal mesothelioma. Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent: Lung Cancer 64:211–218

    CAS  PubMed  Google Scholar 

  28. Baratti D, Kusamura S, Cabras AD, Deraco M (2012) Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol 19:1416–1424

    Article  PubMed  Google Scholar 

  29. Sugarbaker PH (1995) Peritonectomy Procedures. Ann Surg 221:29–42

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Deraco M, Baratti D, Kusamura S et al (2009) Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol 100:321–328

    Article  PubMed  Google Scholar 

  31. Rossi CR, Foletto M, Mocellin S et al (2002) Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 94:492–499

    Article  CAS  PubMed  Google Scholar 

  32. Baratti D, Kusamura S, Cabras AD et al (2010) Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 17:45–53

    Article  PubMed  Google Scholar 

  33. Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242

    Article  PubMed  Google Scholar 

  34. Deraco M, Casali P, Inglese MG et al (2003) Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 83:147–153

    Article  PubMed  Google Scholar 

  35. Deraco M, Baratti D, Kusamura S (2007) Morbidity and quality of life following cytoreduction and HIPEC. Cancer Treat Res 134:403–418

    CAS  PubMed  Google Scholar 

  36. Baratti D, Scivales A, Balestra MR et al (2010) Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol 36:463–469

    Article  CAS  PubMed  Google Scholar 

  37. Baratti D, Kusamura S, Cabras AD et al (2013) Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 49:3140–148

    Article  PubMed  Google Scholar 

  38. Baratti D, Kusamura S, Cabras AD et al (2009) Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 16:463–472

    Article  CAS  PubMed  Google Scholar 

  39. Nonaka D, Kusamura S, Baratti D et al (2005) Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer 104:2181–2188

    Article  PubMed  Google Scholar 

  40. Villa R, Daidone MG, Motta R et al (2008) Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res 14:4134–4140

    Article  CAS  PubMed  Google Scholar 

  41. Perrone F, Jocollè G, Pennati M et al (2010) Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer 46:2837–2848

    Article  CAS  PubMed  Google Scholar 

  42. Baratti D, Vaira M, Kusamura S et al (2010) Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Eur J Surg Oncol 36:1047–1053

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, National Cancer Institute, Milan, Italy

    Marcello Deraco

Authors
  1. Marcello Deraco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dario Baratti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeki Kusamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonello D. Cabras
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Federica Perrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nadia Zaffaroni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcello Deraco .

Editor information

Editors and Affiliations

  1. Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

    Angelo Di Giorgio

  2. Department of Medical, Surgical, and Neurological Sciences, University of Siena, Siena, Italy

    Enrico Pinto

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Italia

About this chapter

Cite this chapter

Deraco, M., Baratti, D., Kusamura, S., Cabras, A.D., Perrone, F., Zaffaroni, N. (2015). Peritoneal Mesothelioma. In: Di Giorgio, A., Pinto, E. (eds) Treatment of Peritoneal Surface Malignancies. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-5711-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5711-1_17

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5710-4

  • Online ISBN: 978-88-470-5711-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation